I.     Introduction

The COVID‑19 pandemic has left a legacy beyond acute infection: for a growing number of individuals, debilitating symptoms persist for months or years, a condition now termed Post‑COVID‑19 Syndrome (PCS) or Long COVID. PCS manifests across multiple organ systems—neurological, respiratory, cardiovascular, gastrointestinal, and immunological and is increasingly recognized as a novel systemic disorder stemming from immune dysregulation [1]. Although initial infection may be mild or asymptomatic, lingering symptoms in a substantial subset of patients suggest complex mechanisms at play [2]. This review delves into the multidimensional immune alterations implicated in PCS, synthesizing emerging literature to chart the pathogenic

landscape and suggest paths toward targeted intervention (Fig 1).

Chronic inflammatory activation is one of the most consistent findings in PCS. Cañas (2023) describes PCS as a virus‑induced systemic inflammatory disorder that arises from a robust acute infection stress-response, which then fails to fully resolve. Elevated pro‑inflammatory markers such as IL‑6, TNF‑α, and IL‑1β—persist in numerous PCS cohorts [3,4], contributing to fatigue, cognitive impairment, and multisystem complaints [1,2]. Notably, IL‑6 elevation correlates with greater symptom burden [3], reinforcing its role in prolonged immune activation.

Beyond systemic inflammation, autoimmunity and autoantibody generation have emerged as key etiological components. Molecular mimicry and sustained antigenic stimulation may break immune tolerance, eliciting auto‑reactive responses [2]. Autoantibodies targeting ACE2, GPCRs, and nuclear antigens have been detected in PCS patients and correlate with cardiovascular and neurological sequelae [5, 6]. Such findings suggest that, for a significant subset of patients, PCS may transition into autoimmune or immune-mediated disease.

Fig. 1: Image of COVID 19

Alterations in cellular immunity further characterize PCS pathology. In a pivotal study by Phetsouphanh et al. (2022), SARS‑CoV‑2–specific T and B‑cell responses remained altered eight months post-infection, with a reduced memory phenotype. Similarly, Haunhorst et al. (2022) documented persistent lymphopenia and functional impairment in T‑cell compartments up to twelve months after infection. Su et al. (2022) identified early markers predictive of PCS, including dysregulated monocyte profiles and T‑cell exhaustion phenotypes. Persistent immune activation—including increased CD14⁺CD16⁺ monocytes—suggests ongoing innate-adaptive crosstalk [7].

Gut‑immune axis dysbiosis is an increasingly recognized facet of PCS. Galán et al. (2023) summarize how chronic gut inflammation and microbiome alterations persist in the post‑acute period, potentially perpetuating systemic inflammation and neuroimmune dysregulation[8]. This may contribute to gastrointestinal symptoms and fatigue, reinforcing the interconnected nature of gut and systemic immunity[9].

Mast cell hyperactivation has also been implicated. Cañas (2023) and Bani‑Hani et al. (2023) note overlap between PCS and mast cell activation syndromes, with reports of histamine-mediated symptoms including rashes, gastrointestinal disturbance, and “brain fog.” Unremitting mast cell mediator release may act as a persistent amplifier of inflammatory and neurological symptoms[1,6].

The heterogeneity of PCS is underscored by Haunhorst et al. (2022), who found divergent immune phenotypes across pulmonary versus neurological symptom profiles, emphasizing distinct yet overlapping immune pathways[4]. Moreover, Altmann and Boyton (2023) advocate a stratified immunological model, differentiating inflammatory, autoimmune, viral persistence, and autonomic subtypes—each with unique biomarker and therapeutic implications[2].

Persistent viral components may also sustain immune activation. Cañas (2023) reviews evidence of residual SARS‑CoV‑2 RNA or proteins in tissues, including the gut and lungs, months after viral clearance. Such antigen persistence could chronically stimulate innate and adaptive immunity, accounting for relapsing symptoms and immune remodelling [1,2].Gender differences are notable: PCS disproportionately affects females [2,4], possibly reflecting innate sex-based immune responses and a greater predisposition to autoimmunity [10]. Dissecting these differences may help guide personalized diagnostic and treatment approaches.

Immune dysregulation in PCS is typified by chronic inflammation, autoimmunity, cellular immune dysfunction, gut‑brain axis disruption, mast cell activation, and potential antigen persistence. This multi-axis paradigm underscores the complexity of PCS and challenges one-size-fits-all treatment paradigms. Immunotherapy trials—exploring anti‑cytokine agents, antiallergics, and immunomodulators—are underway [2,3], and granularity in biotype identification will be essential to targeting interventions effectively. In synthesizing current evidence, this comprehensive review aims to: (1) delineate the immunopathogenic pathways driving PCS, (2) highlight immune-based clinical and sex-based phenotypes, and (3) evaluate current and forthcoming immunotherapeutic strategies. Through this, we aim to foster a biologically-informed classification system and advance therapeutic precision for millions living with Post‑COVID‑19 Syndrome (Fig 2).

Fig. 2: The Immunopathogenic Pathways in Post-COVID-19 Syndrome[10]

1. Persistent Immune Activation

Individuals with long COVID exhibit ongoing immune activation that persists for months following the acute phase. Elevated activation of both CD4⁺ and CD8⁺ T cells—marked by HLA‑DR, CD38, Ki‑67, and granzyme B—as well as increased cytokines IL‑4, IL‑7, IL‑17, and TNF‑α in patients three months post-infection, particularly those who had severe disease[11]. This immune activation persisted without direct correlation to long COVID symptoms after adjusting for severity, suggesting a distinct yet lasting immunological signature(Fig. 3).

Impaired type I interferon responses and excessive pro-inflammatory cytokine production in acute severe COVID-19 may set the stage for chronic immune dysfunction[12]. This acute “cytokine storm” likely primes a sustained inflammatory milieu. Machine learning–based immunopheno typing to reveal persistent inflammation, dysregulated cytokine profiles, and altered immune cell subsets in long COVID up to a year post-infection[13].

Figure 3: Cellular and Molecular Features of Persistent Immune Activation[13]

Finally, exhaustion markers PD‑1 and TIM‑3 remain elevated on T cells, as demonstrated [14], indicating chronic antigenic stimulation and potential immune fatigue. These findings collectively underscore a prolonged, multifaceted immune activation—characterized by inflammation, T-cell exhaustion, and immune dysregulation—contributing to long COVID pathophysiology.

2. Autoimmunity and Autoantibodies

Growing evidence indicates that SARS‑CoV‑2 infection can trigger autoimmunity, contributing significantly to post-acute sequelae of COVID‑19. Multiple studies have documented the emergence of novel autoantibodies—against ACE2, β₂-adrenoceptor, muscarinic receptors, AT₁ receptor, and others—that persist for months post-infection [11]. One prominent study found that as many as 81% of convalescent individuals had autoantibodies to ACE2, which inhibited its enzymatic activity and likely exacerbated inflammation via angiotensin II accumulation . Larger proteome-wide analyses revealed a diverse repertoire of new-onset autoantibodies in both mild and severe COVID-19 cases, with many remaining elevated over 12 months [15]. Autoantigen profiling confirmed a distinct autoreactive signature in post-COVID individuals compared to never-infected controls, although such patterns were not reliably distinguishable between long COVID and fully recovered cohorts [16]. Emerging research also points to anti idio type antibodies targeting ACE2 post-infection or vaccination, which may promote autoimmune neurological manifestations [17]. These findings collectively suggest that SARS‑CoV‑2 infection may provoke persistent immune dysregulation via molecular mimicry, anti‑idiotype generation, and sustained autoantibody production, underscoring the potential for autoimmune-driven symptoms in long COVID.

3. T‑Cell Dysfunction in Long COVID

Long COVID is marked by enduring T‑cell dysfunction, including reduced repertoire diversity, functional exhaustion, and altered memory subset distributions. A study by Tunheim et al. in Nature Immunology revealed skewed central and effector memory CD4⁺/CD8⁺ T-cell profiles with elevated exhaustion markers PD‑1 and TIM‑3 persisting ≥8 months post-infection [18]. Elevated terminal effector CD4⁺ TEMRA and exhausted CD8⁺ CD28⁻ CD27⁻ T-cell populations were observed in Respiratory Research, especially in individuals with chronic pulmonary symptoms. Single-cell analyses from Frontiers in Immunology showed notable depletion of overall CD3⁺ and CD8⁺ memory T cells, with incomplete recovery at 6 months. T-cell receptor sequencing in PMC and NCBI cohorts reported reduced TCR-β diversity and clonal expansions consistent with chronic antigen exposure. Although SARS‑CoV‑2–specific CD8⁺ responses remain detectable, functional competence remains impaired, indicating persistent exhaustion. Collectively, these findings underscore a prolonged state of T-cell dysregulation that likely contributes to impaired immune surveillance, viral persistence, and the chronic symptomatology of Long COVID.

4. Gut Dysbiosis in Long COVID

Gut dysbiosis, defined as an imbalance in the composition and function of the gut microbiota, has been increasingly associated with Long COVID. The gut microbiome is critical for maintaining immune homeostasis and modulating inflammatory responses. In individuals with Long COVID, studies have reported a significant reduction in beneficial bacteria such as Faecalibacterium prausnitzii and Eubacterium rectale, accompanied by an increase in opportunistic pathogens like Ruminococcus gnavus and Clostridium hathewayi [19]. This microbial imbalance may lead to enhanced gut permeability, facilitating the translocation of bacterial products and promoting systemic inflammation. Moreover, dysbiosis has been linked to the persistence of gastrointestinal symptoms commonly reported in Long COVID, such as bloating, diarrhea, and abdominal pain. Understanding the role of gut microbiota in post-viral syndromes may offer new therapeutic strategies for managing long-term symptoms of COVID-19.

5. Vascular Inflammation and Coagulopathy in Long COVID

Long COVID has been associated with persistent vascular inflammation and coagulopathy, marked by endothelial dysfunction and microvascular thrombosis. The endothelium, which plays a crucial role in vascular homeostasis, may remain activated or damaged post-infection due to unresolved inflammation and immune dysregulation. Studies have reported elevated markers of endothelial injury, including von Willebrand factor and soluble thrombomodulin, in long COVID patients [20]. This chronic endothelial activation can promote platelet aggregation and thrombin generation, increasing the risk of thromboembolic events. Additionally, persistent microvascular dysfunction has been implicated in organ-specific complications such as myocarditis, brain fog, and fatigue. The procoagulant state in long COVID may also involve autoimmune mechanisms, including the presence of antiphospholipid antibodies. Recognizing these vascular abnormalities is essential for early identification and management of long-term cardiovascular and thrombotic risks in post-COVID patients.

6. Recovery and Immune Restoration in Long COVID

Emerging longitudinal studies suggest that immune dysfunction associated with Long COVID may gradually improve over time in a subset of individuals. By 24 months post-infection, normalization of T-cell subsets, including CD4⁺ and CD8⁺ memory cells, along with reduced expression of exhaustion markers such as PD-1 and TIM-3, has been reported [21]. These findings indicate a partial restoration of immune homeostasis, potentially contributing to symptom resolution. Concurrently, improvements in patient-reported outcomes—such as reduced fatigue, better cognitive function, and enhanced physical performance—support the notion of recovery in some long COVID cases. However, the pace and extent of immune restoration vary widely among individuals, with some showing prolonged abnormalities or relapses. Understanding these recovery trajectories is essential for identifying prognostic markers and guiding long-term management and rehabilitation strategies for affected individuals.

7. Therapeutic Implications in Long COVID

The recognition of immune dysregulation in Long COVID has significant therapeutic implications, prompting exploration into targeted interventions. Immunomodulatory treatments, such as low-dose corticosteroids, cytokine inhibitors (e.g., IL-6 blockers), and JAK inhibitors, are being investigated to mitigate chronic inflammation and immune overactivation [22]. These therapies aim to restore immune balance and reduce systemic symptoms such as fatigue, brain fog, and myalgia. Additionally, given the role of gut dysbiosis in sustaining inflammation, interventions targeting the gut microbiota—such as probiotics, prebiotics, and dietary modifications—may help in reestablishing microbial equilibrium and improving gastrointestinal and systemic outcomes [19]. Personalized treatment approaches based on immune profiling are also gaining attention to better tailor therapy to individual patient needs. Overall, a multi-targeted strategy addressing both immune and microbiome imbalances holds promise in managing the complex symptomatology of Long COVID.

II. Conclusion

Post-COVID-19 Syndrome (PCS) presents a multifaceted challenge, rooted in complex immune dysregulation that extends beyond the acute infection phase. This review highlights the key pathological contributors—chronic inflammation, autoimmunity, T-cell exhaustion, gut dysbiosis, and endothelial dysfunction—each playing a critical role in the persistence of long COVID symptoms. The presence of autoantibodies, sustained pro-inflammatory cytokines, and disrupted immune cell profiles underscores the potential transition of PCS into an immune-mediated or autoimmune condition for many patients. Furthermore, gut microbiota imbalances and persistent viral components exacerbate systemic immune activation, contributing to symptoms such as fatigue, brain fog, and gastrointestinal disturbances. Despite these challenges, emerging evidence offers hope, as some individuals show signs of immune normalization within 18–24 months. Ongoing clinical research into immunomodulatory treatments and personalized therapy based on immune phenotypes marks a significant step forward. However, due to the heterogeneity of long COVID, a one-size-fits-all treatment remains ineffective. A stratified, biomarker-driven approach is essential to improving outcomes. Continued investigation is vital not only to clarify the underlying mechanisms but also to develop targeted interventions. Understanding PCS through the lens of immune dysregulation provides the foundation for more effective therapies, ultimately improving the quality of life for millions affected by this long-term condition.